Nan Li
Co-Founder @ Dimension Capital
San Francisco, United States
Nan Li is a Series A investor at Dimension Capital in San Francisco focused on Software and Health Care. Nan joined Innovation Endeavors in 2013. Prior to this, he led Operations, Product, and Finance at a high-growth startup in San Francisco called Gigwalk. The company operated a B2B2C marketplace to connect businesses with real-time workers ready to do tasks. Before Gigwalk, Nan was an investor at Bain Capital Ventures, focused on early-stagecompanies in commerce, media, and data. Earlier in his career, he also served as a product manager at Microsoft as well as a strategy consultant at Bain & Company.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 71%
Last updated:
For AI agents: llms.txt
Industries Nan Li invests in
Stages Nan Li invests in
Countries Nan Li invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Software 5 (29%)
- Health Care 5 (29%)
- Artificial Intelligence 5 (29%)
- Biotechnology 4 (24%)
- Machine Learning 4 (24%)
Stage
- Series A 7 (41%)
- Seed 4 (24%)
- Series B 2 (12%)
- Series C 2 (12%)
- Series D 1 (6%)
Country
- United States 8 (47%)
- United Kingdom 2 (12%)
- Canada 1 (6%)
- France 1 (6%)
- Germany 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Iterative Health is a healthcare technology and services company that focuses on accelerating clinical research to improve patient outcomes through innovative approaches. The company transforms gastrointestinal (GI) care by utilizing AI-driven clinical trials and diagnostics, significantly enhancing access to vital treatments. | $77M / Series C / Apr 30, 2026 | ||
| Tamarind Bio is a software company that help the scientists and researchers using computational tools in biology. | $13.6M / Series A / Feb 24, 2026 | ||
| Automata is a deep-tech company that creates products that empower people to automate physical work. The company's product, Eva, is a lightweight and affordable robot arm built for professionals in a production line, in a lab, a home workshop or even in a classroom. People don't need to be technical experts to communicate with robots. Theweb-based software platform can be programmed by anyone, anywhere, any time, from any device, making it easy to reconfigure for a wide range of different tasks.Automata was founded on 2015 and is headquartered in London, England. | $45M / Series C / Jan 29, 2026 | ||
| Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. | $213M / Series D / Sep 10, 2025 | ||
| We build the frameworks, tools, and infrastructure that developers need to quickly prototype, productize, and operationalize analytical workflows. | $17M / Series A / Sep 04, 2025 | ||
| Convoke is curating high-quality datasets, automating workflows, and building a software platform. | $8.6M / Seed / Aug 19, 2025 | ||
| Accelerate drug time to market through real study traceability and unparalleled trial integrity | $4.3M / Seed / May 29, 2025 | ||
| Aspect Biosystems is a privately held biotechnology company combining the power of microfluidics and 3D bioprinting to fuel medical research and the development of bioprinted therapeutics. By adopting Aspect’s microfluidic 3D bioprinting platform and collaborating within Aspect’s network, researchers worldwide are accelerating the development andcommercialization of 3D bioprinted tissues. In addition, Aspect is advancing its internal regenerative medicine programs focused on metabolic diseases and musculoskeletal injuries and disorders and partnering with key industry players to bring bioprinted therapeutics to the clinic. | $115M / Series B / Jan 08, 2025 | ||
| Automata is a deep-tech company that creates products that empower people to automate physical work. The company's product, Eva, is a lightweight and affordable robot arm built for professionals in a production line, in a lab, a home workshop or even in a classroom. People don't need to be technical experts to communicate with robots. Theweb-based software platform can be programmed by anyone, anywhere, any time, from any device, making it easy to reconfigure for a wide range of different tasks.Automata was founded on 2015 and is headquartered in London, England. | $40M / Oct 02, 2023 | ||
| Iterative Scopes delivers tools for physicians and life sciences in colorectal cancer and inflammatory bowel disease space. The company was founded in 2017 and is based in Cambridge, Massachusetts. | $150M / Series B / Jan 19, 2022 | ||
| See all 17 investments → | |||
Co-Investors
About Dimension Capital
Dimension is a first-of-its-kind firm partnering with founders at the interface of technology and life sciences to transform the trajectory of life on earth. The firm partners with leading entrepreneurs to build the next generation of tech and bio businesses. The company was founded by Nan Li, Adam Goulburn, and Zavain Dar in March 2022 and isbased in New York, NY and San Francisco, CA.
Dimension Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Adam Goulburn
Founder & Managing Partner
|
|||
Michele Vlcek
Operations Manager
|
|||
|
Nan Li
Co-Founder
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Nan Li invest in?
Nan Li invests primarily in Software, Health Care and Artificial Intelligence startups, most often at Series A and Seed stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Nan Li?
Public channels for Nan Li include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Nan Li last invest?
The most recent investment recorded for Nan Li closed in Apr 2026. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
